Kristina Sjöblom Nygren
Director/Board Member at INFANT BACTERIAL THERAPEUTICS AB
Net worth: 748 $ as of 31/03/2024
Profile
Kristina Sjöblom Nygren is an Independent Director at Infant Bacterial Therapeutics AB since 2018.
She was previously a Group Director-Development at Astrazeneca AG from 2007 to 2008 and a Medical Director at Pfizer AG from 1998 to 2003.
She also served as the Chief Medical Officer, EVP & Head-Development at Santhera Pharmaceuticals Holding AG from 2017 to 2020.
Additionally, she was a Vice President & Head-Clinical Development at Swedish Orphan Biovitrum AB.
Dr. Sjöblom Nygren holds a doctorate degree from Karolinska Institutet.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
31/12/2022 | 100 ( 0.00% ) | 748 $ | 31/03/2024 |
Kristina Sjöblom Nygren active positions
Companies | Position | Start |
---|---|---|
INFANT BACTERIAL THERAPEUTICS AB | Director/Board Member | 15/05/2018 |
Former positions of Kristina Sjöblom Nygren
Companies | Position | End |
---|---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Chief Tech/Sci/R&D Officer | 31/12/2020 |
Astrazeneca AG | Corporate Officer/Principal | 01/01/2008 |
Pfizer AG | Chief Tech/Sci/R&D Officer | 01/01/2003 |
SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Training of Kristina Sjöblom Nygren
Karolinska Institutet | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
INFANT BACTERIAL THERAPEUTICS AB | Health Technology |
Private companies | 2 |
---|---|
Astrazeneca AG | |
Pfizer AG |
- Stock Market
- Insiders
- Kristina Sjöblom Nygren